Immunohistochemical Expression of FXR1 in Canine Normal Tissues and Melanomas.

Publisher: SAGE Publications Country of Publication: United States NLM ID: 9815334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1551-5044 (Electronic) Linking ISSN: 00221554 NLM ISO Abbreviation: J Histochem Cytochem

Publication: <2011->: Thousand Oaks, CA : SAGE Publications
Original Publication: Baltimore : Williams & Wilkins Co., c1953-

Dog Diseases/*pathology ; Immunohistochemistry/*methods ; Melanoma/*veterinary ; Mouth Neoplasms/*veterinary ; RNA-Binding Proteins/*analysis ; Uveal Neoplasms/*veterinary; Animals ; Antibodies/analysis ; Blotting, Western ; Dogs ; Goats ; Humans ; Melanoma/pathology ; Mouth Neoplasms/pathology ; Rabbits ; Uveal Neoplasms/pathology

Fragile X mental retardation-related protein 1 (FXR1) is a cytoplasmic RNA-binding protein highly conserved among vertebrates. It has been studied for its role in muscle development, inflammation, and tumorigenesis, being related, for example, to metastasizing behavior in human and canine uveal melanoma. Anti-FXR1 antibodies have never been validated in the canine species. To investigate FXR1 expression in canine melanocytic tumors, the present study tested two commercially available polyclonal anti-human FXR1 antibodies, raised in goat and rabbit, respectively. The cross-reactivity of the anti-FXR1 antibodies was assessed by Western blot analysis, and the protein was localized by IHC in a set of normal canine tissues and in canine melanocytic tumors (10 uveal and 10 oral). Western blot results demonstrated that the antibody raised in rabbit specifically recognized the canine FXR1, while the antibody raised in goat did not cross-react with this canine protein. FXR1 protein was immunodetected using rabbit anti-FXR1 antibody, in canine normal tissues with different levels of intensity and distribution. It was also detected in 10/10 uveal and 9/10 oral melanocytic tumors. The present study validated for the first time the use of anti-FXR1 antibody in dogs and highlighted different FXR1 protein expression in canine melanocytic tumors, the significance of which is undergoing further investigations.

J Neuropathol Exp Neurol. 1999 Aug;58(8):867-80. (PMID: 10446811)
Hum Mol Genet. 1995 Dec;4(12):2209-18. (PMID: 8634689)
J Biol Chem. 2005 Feb 18;280(7):5750-63. (PMID: 15548538)
J Small Anim Pract. 2013 Nov;54(11):584-93. (PMID: 24580015)
Acta Biochim Biophys Sin (Shanghai). 2014 Feb;46(2):119-27. (PMID: 24389646)
Brain Res Bull. 2001 Oct-Nov 1;56(3-4):375-82. (PMID: 11719275)
EMBO J. 1995 Jun 1;14(11):2401-8. (PMID: 7781595)
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3469-74. (PMID: 25733852)
Pathologe. 1987 May;8(3):138-40. (PMID: 3303008)
Tumour Biol. 2016 Feb;37(2):2683-90. (PMID: 26404134)
Neuron. 2010 Feb 11;65(3):373-84. (PMID: 20159450)
Biol Reprod. 2013 Sep 27;89(3):68. (PMID: 23926281)
FEBS J. 2010 Jul;277(13):2754-65. (PMID: 20491901)
PLoS Genet. 2013 Mar;9(3):e1003367. (PMID: 23555284)
J Mol Diagn. 2010 Jul;12(4):461-8. (PMID: 20413675)
Genomics. 1999 Jul 15;59(2):193-202. (PMID: 10409431)
Cell Cycle. 2016 Jul 17;15(14):1874-82. (PMID: 27229378)
Arch Pathol Lab Med. 2014 Dec;138(12):1564-77. (PMID: 25427038)
EMBO J. 1995 Nov 1;14(21):5358-66. (PMID: 7489725)
Vet Pathol. 2013 Nov;50(6):1007-15. (PMID: 23558974)
Int J Cancer. 2007 Jun 15;120(12):2538-44. (PMID: 17290396)

Keywords: FXR1; IHC; Western blot; dog; eye; melanoma; neoplasia; oral cavity

0 (Antibodies)
0 (RNA-Binding Proteins)

Uveal melanoma

Date Created: 20180403 Date Completed: 20190730 Latest Revision: 20190802

20240513

PMC6071178

10.1369/0022155418766292

29608406